Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Batmunkh, Tsetsegsaikhan, Moore, Kerryn A, Thomson, Helen, Altangerel, Bolor, Amraa, Otgonjargal, Avaa, Naranbaatar, Batbayar, Lkhagvagaram, Batsukh, Khishigjargal, Bright, Kathryn, Burentogtokh, Tsogjargal, Ha Do, Lien Anh, Dorj, Gantuya, Hart, John D, Javkhlantugs, Khulan, Jigjidsuren, Sarantsetseg, Justice, Frances, Li, Shuo, Licciardi, Paul V, Mashbaatar, Khaliunaa, Mazarakis, Nadia, Neal, Eleanor F G, Nguyen, Cattram Duong, Ochirbat, Batbayar, Tsolmon, Bilegtsaikhan, Tuya, Alimaa, Surenjav, Unursaikhan, von Mollendorf, Claire, Mulholland, Kim
Published in The Lancet regional health. Western Pacific (01.01.2024)
Published in The Lancet regional health. Western Pacific (01.01.2024)
Get full text
Journal Article